These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 27479786

  • 1. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC.
    Artiko V, Afgan A, Petrović J, Radović B, Petrović N, Vlajković M, Šobić-Šaranović D, Obradović V.
    Nucl Med Rev Cent East Eur; 2016; 19(2):99-103. PubMed ID: 27479786
    [Abstract] [Full Text] [Related]

  • 2. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 3. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
    Trogrlic M, Tezak S.
    Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
    [Abstract] [Full Text] [Related]

  • 4. The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.
    Artiko V, Sobic-Saranovic D, Pavlovic S, Petrovic M, Zuvela M, Antic A, Matic S, Odalovic S, Petrovic N, Milovanovic A, Obradovic V.
    J BUON; 2012; 17(3):537-42. PubMed ID: 23033296
    [Abstract] [Full Text] [Related]

  • 5. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
    Sergieva S, Robev B, Dimcheva M, Fakirova A, Hristoskova R.
    Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
    [Abstract] [Full Text] [Related]

  • 6. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy.
    Garai I, Barna S, Nagy G, Forgacs A.
    Nucl Med Rev Cent East Eur; 2016; 19(2):93-8. PubMed ID: 27479887
    [Abstract] [Full Text] [Related]

  • 7. 99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors.
    Gabriel M, Muehllechner P, Decristoforo C, von Guggenberg E, Kendler D, Prommegger R, Profanter C, Moncayo R, Virgolini I.
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):237-44. PubMed ID: 16172569
    [Abstract] [Full Text] [Related]

  • 8. Quantitative analysis of standardized uptake values (SUV) of metastatic bone lesions in scintigraphy with [99mTc]Tc-EDDA/HYNIC-Tyr3-octreotide in patients with neuroendocrine tumours.
    Malarz MM, Birkenfeld B, Piwowarska-Bilska H.
    Nucl Med Rev Cent East Eur; 2024 Sep; 27(0):31-35. PubMed ID: 39162352
    [Abstract] [Full Text] [Related]

  • 9. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
    Płachcińska A, Mikołajczak R, Kozak J, Rzeszutek K, Kuśmierek J.
    Nucl Med Rev Cent East Eur; 2006 Sep; 9(1):24-9. PubMed ID: 16791800
    [Abstract] [Full Text] [Related]

  • 10. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
    Czepczyński R, Gryczyńska M, Ruchała M.
    Nucl Med Rev Cent East Eur; 2016 Sep; 19(2):67-73. PubMed ID: 27479883
    [Abstract] [Full Text] [Related]

  • 11. Incremental value of 99mTc-HYNIC-TOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours.
    Trogrlic M, Težak S.
    Nuklearmedizin; 2017 Jun 12; 56(3):97-107. PubMed ID: 28164207
    [Abstract] [Full Text] [Related]

  • 12. Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience.
    Reilly C, Gemmell AJ, McLaughlin IM, Fleming R, Reed N, McIntosh D, Nicol A.
    Nucl Med Commun; 2021 Aug 01; 42(8):935-939. PubMed ID: 33741866
    [Abstract] [Full Text] [Related]

  • 13. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct 01; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 14. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R.
    J Nucl Med; 2003 May 01; 44(5):708-16. PubMed ID: 12732671
    [Abstract] [Full Text] [Related]

  • 15. [99mTc-OCTREOTIDE in patients with neuroendocrine tumors from the GI tract].
    Gómez M, Ferrando R, Vilar J, Hitateguy R, López B, Moreira E, Kapitán M, De Lima F, Agüero B, Gabriela Villegas M, Urdaneta N, Gutiérrez E, Battegazzore A, Bayardo K, Silveira A, Lago G, Páez A.
    Acta Gastroenterol Latinoam; 2010 Dec 01; 40(4):332-8. PubMed ID: 21381408
    [Abstract] [Full Text] [Related]

  • 16. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
    Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2005 Dec 01; 32(12):1440-51. PubMed ID: 16133384
    [Abstract] [Full Text] [Related]

  • 17. Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors.
    Sepúlveda-Méndez J, de Murphy CA, Pedraza-López M, Murphy-Stack E, Rojas-Bautista JC, González-Treviño O.
    Nucl Med Commun; 2012 Jan 01; 33(1):69-79. PubMed ID: 21970835
    [Abstract] [Full Text] [Related]

  • 18. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).
    Briganti V, Cuccurullo V, Berti V, Di Stasio GD, Linguanti F, Mungai F, Mansi L.
    Curr Radiopharm; 2020 Jan 01; 13(3):166-176. PubMed ID: 31886756
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
    Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ.
    J Nucl Med; 2007 Apr 01; 48(4):508-18. PubMed ID: 17401086
    [Abstract] [Full Text] [Related]

  • 20. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
    Parisella MG, Chianelli M, D'Alessandria C, Todino V, Mikolajczak R, Papini E, Dierckx RA, Scopinaro F, Signore A.
    Q J Nucl Med Mol Imaging; 2012 Feb 01; 56(1):90-8. PubMed ID: 21068709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.